Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids. Zynerba Pharmaceuticals has been …

Aug 14, 2023 · Under the terms of the definitive agreement, which was unanimously approved by the boards of directors of Harmony and Zynerba, Harmony will commence a tender offer to …

Oct 11, 2023 · HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE. New product in development diversifies …

An in vitro (performed in a lab in a test tube, culture dish, or elsewhere outside of a living organism) study, titled “Identification of Psychoactive Degradants of Cannabidiol in Simulated …

Advancing science. Improving connections. We focus our research and development efforts on rare (affecting fewer than 200,000 patients in the U.S.) neuropsychiatric conditions. Our lead …

Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare …

14 Sep 23 Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) …

Jul 21, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are …

Oct 11, 2023 · The Zynerba Board of Directors unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer. Key Information to Know. Tender …

Aug 14, 2017 · Zynerba’s ZYN002 CBD gel is the first and only pharmaceutically-produced CBD formulated as a patent-protected permeation-enhanced gel and is being studied in adult …